Skip to main content
Journal cover image

Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Publication ,  Journal Article
Dickinson, MG; Ip, JH; Olshansky, B; Hellkamp, AS; Anderson, J; Poole, JE; Mark, DB; Lee, KL; Bardy, GH; SCD-HeFT Investigators,
Published in: Am Heart J
April 2007

BACKGROUND: Recent observations suggest statin treatment may be associated with lower mortality in heart failure (HF). The SCD-HeFT was a study of 2521 functional class II and III HF patients with left ventricular ejection fractions < or = 35% and ischemic and nonischemic cardiomyopathy followed up for a median of 45.5 months. The study length, size, and degree of background HF, including the use of implantable defibrillator therapy, provide a unique opportunity to evaluate the impact of statin use in HF with mechanistic insights from subgroup analyses. METHODS AND RESULTS: Statin use was reported in 965 (38%) of 2521 patients at baseline and 1187 (47%) at last follow-up. The relationships between statin use, randomization arm, disease category, and functional class and all cause mortality were assessed. Statin use was studied as a time-dependent covariate in a multivariable Cox proportional hazards model, adjusted for imbalances between statin and no-statin groups. Mortality risk was significantly lower in those taking a statin (HR [95% CI], 0.70 [0.58-0.83]). Mortality risk was lower with statin use in all prespecified subgroups: ischemic cardiomyopathy (0.69 [0.56-0.86]), nonischemic cardiomyopathy (0.67 [0.47-0.96]), implantable cardioverter defibrillator (ICD) (0.66 [0.46-0.95], non-ICD (0.71 [0.57-0.87]), New York Heart Association II (0.62 [0.48-0.79]), and New York Heart Association III (0.79 [0.61-1.03]). CONCLUSIONS: Statin use is associated with reduced all-cause mortality in HF patients. Statins appear to benefit patients with nonischemic and ischemic cardiomyopathy similarly. Statin benefits are similar in ICD and non-ICD patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2007

Volume

153

Issue

4

Start / End Page

573 / 578

Location

United States

Related Subject Headings

  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Follow-Up Studies
  • Female
  • Defibrillators, Implantable
  • Cardiovascular System & Hematology
  • Cardiomyopathies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dickinson, M. G., Ip, J. H., Olshansky, B., Hellkamp, A. S., Anderson, J., Poole, J. E., … SCD-HeFT Investigators, . (2007). Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J, 153(4), 573–578. https://doi.org/10.1016/j.ahj.2007.02.002
Dickinson, Michael G., John H. Ip, Brian Olshansky, Anne S. Hellkamp, Jill Anderson, Jeanne E. Poole, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy, and Gust H. SCD-HeFT Investigators. “Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).Am Heart J 153, no. 4 (April 2007): 573–78. https://doi.org/10.1016/j.ahj.2007.02.002.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2007

Volume

153

Issue

4

Start / End Page

573 / 578

Location

United States

Related Subject Headings

  • Myocardial Ischemia
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Follow-Up Studies
  • Female
  • Defibrillators, Implantable
  • Cardiovascular System & Hematology
  • Cardiomyopathies